Product Detail

Using the DSM-5® and ICD-10 AND Psychopharmacology for Mental Health Professionals
Package - Video
$399.98 USD
Product Details
Package - Video   Instructions
Multi-disc DVD recording (11 hours, 40 minutes) with electronic manual and instructions.
PESI Publishing & Media
CE Available:
Yes, See CE credit tab for complete continuing education details
Product Code:
[+] [-] 045900 - Using the DSM-5® and ICD-10: The Changing Diagnosis of Mental Disorders
  1. Identify the major revisions in DSM-5® to substance, mood, anxiety, and other common categories of mental disorders.
  2. Describe five changes in the organization of mental disorder categories in the DSM-5®.
  3. Discuss the diagnostic criteria for six or more new diagnoses in the DSM-5®.
  4. Describe the ICD and its relationship to the DSM-5® in classifying mental disorders.
  5. Convert a DSM-IV-TR® Axis I diagnosis (name, code, and specifiers) to a DSM-5® diagnosis (name, code, and specifiers) and apply an ICD-10 code.
  6. Utilize the DSM-5® criteria to diagnose clients in case studies during the workshop.

[+] [-] 045905 - Psychopharmacology for Mental Health Professionals
  1. Communicate the neurotransmitter systems and neuroanatomy underlying the biological basis for mental disorders and pharmacotherapy.
  2. Evaluate the role of mental health professionals who treat clients receiving both psychotherapeutic medications and psychotherapy.
  3. Analyze the major classes of drugs used to treat mental disorders and which mental disorders are appropriately treated with each class of drugs.
  4. Compare the effects and side effects of various psychotropic medications, including antipsychotics, antidepressants, benzodiazepines and anticonvulsants.
  5. Determine the abuse liability of drugs used in the treatment of anxiety, insomnia, pain and ADHD.
  6. Implement methods for prevention and early identification of prescription drug abuse among clients.

[+] [-] 045900 - Using the DSM-5® and ICD-10: The Changing Diagnosis of Mental Disorders
Organization & Structure
Development of the DSM-5®
  • Rationale for a new version
  • Work group goals for improving the DSM®
  • Summary of the areas of controversy
Changes in the Organization of the DSM-5®
  • New Definition of Mental Disorder
  • Eliminating the axis
  • Life-Span approach in all mental disorders
  • Mental disorders as dimensional and categorical
  • Don’t forget the Appendix!
Alignment with the ICD-10
  • ICD-10 Codes for Mental Disorders
  • How clinicians use the ICD-10
Changes in Major Mental Disorders
Neurocognitive Disorders
  • Major Neurocognitive Disorder
  • What happened to Dementia?
  • Alzheimer’s Disorder
  • Mild Neurocognitive Disorder
  • Mild Traumatic Brain Injury
Neurodevelopmental Disorders
  • Autism Spectrum Disorder
  • Only disorder with tightened criteria
  • What happened to Asperger’s?
  • Social Communication Disorder
  • The ever-changing ADHD
  • Intellectual Development Disorder
The Schizophrenia Spectrum and Other Psychotic Disorders
  • Schizophrenia
  • What happened to the subtypes?
  • Delinking catatonia
  • Revised Schizoaffective Disorder
  • Schizophrenia video case and discussion
Two Mood Disorders Categories
  • Depressive Disorders
  • Removal of the bereavement criteria
  • Changes to criteria
  • Bipolar and related disorders
  • Disruptive Mood Deregulation Disorder
  • Clarifying Bipolar I and II
  • Video clips of mood symptoms and discussion
Three Anxiety Related Categories
  • Anxiety Disorders: What is left?
  • Obsessive-Compulsive and related disorders
  • Hoarding Disorder
  • Trauma and Stress related disorders
  • Posttraumatic Stress Disorder changes
  • Adjustment disorders
  • Client Case Activity: GAD and PTSD
Substance Use and Addictive Disorders
  • Dropping abuse and dependence
  • Changes for various substance use disorders
  • Gambling addiction
  • Prescription drugs and addiction
Reformulated Disorders of Behavior
Feeding and Eating Disorders
  • New Binge Eating Disorder
  • New Avoidant/Restrictive Food Intake Disorder
  • Changes to Anorexia and Bulimia Nervosa
  • Feeding disorders across the life-span
Disruptive, Impulse Control, and Conduct Disorders
  • Oppositional Defiant Disorder
  • Conduct Disorder
  • Intermittent Explosive Disorder
DSM-5® and the ICD-10
Coding Protocol from the DSM-IV® to DSM-5®
Using the ICD-10 Classification
Case Study of conversion from a DSM-IV® diagnosis

[+] [-] 045905 - Psychopharmacology for Mental Health Professionals
Core Pharmacological Principles
  • Brain structures & circuits involved in:
    • Emotional regulation
    • Executive function & inhibitory control
    • Reward & pleasure
    • Learning & memory
  • Receptors and neurotransmitters important in the actions of psychopharmacological agents
    • Biogenic amines
    • Excitatory & inhibitory neurotransmitters
    • Endorphins & endocannabinoids
Your Role in Combined Psychological & Pharmacological Treatments
  • Collaboration & communication with prescribing professionals
  • Managing the combined treatments
    • Referrals for medication
    • Client psycho-education
    • Monitoring drug effects & side effects
    • Promoting adherence to combined treatments
Depressive Disorders
  • Neurobiology of depression
  • Drugs used to treat depressive disorders
    • Selective Serotonin Reuptake inhibitors (SSRIs)
      • Effects, side effects and cautions
      • Suicide risk & discontinuation syndrome
      • Serotonin syndrome
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Effects, side effects, and cautions
  • Atypical antidepressant agents
    • Effects, side effects, and cautions
  • Tricyclic antidepressants (TCAs)
    • Effects, side effects, and cautions
    • Why were newer drugs needed?
  • MAO inhibitors
    • Effects, side effects, and cautions
  • Choosing an antidepressant
  • What if first-line antidepressants do not work?
    • Augmentation with antipsychotics
  • What about herbs like St. John’s Wort?
Schizophrenia Spectrum Disorders
  • Biological theories of schizophrenia
  • ”Typical” & “atypical” antipsychotic drugs
    • Effects, side effects & cautions – similarities & differences
  • Latest evidence-based comparisons
  • Drugs for treatment-resistant schizophrenia
  • Other uses of antipsychotic drugs
Bipolar Disorders
  • Biological theories for bipolar disorders
  • Drugs used to treat bipolar disorders
    • A prototype agent-lithium
      • Effects, side effects & cautions
    • Anticonvulsants
      • Effects, side effects & cautions
    • Antipsychotics – approved agents
    • Combination drug therapy
Anxiety, Obsessive-Compulsive & Sleep-Wake Disorders
  • The neurobiology of anxiety-related disorders
  • The structure of sleep
  • Drugs used in the treatment of anxiety & insomnia
    • Benzodiazepines & Benzodiazepine-like drugs
    • Misuse of these drugs in treatment
    • SSRI’s & other drugs used to treat anxiety
Attention-Deficit/Hyperactivity Disorder & Neurocognitive Disorders (Dementia)
  • ADHD
    • Psycho-stimulants
      • Effects, side effects & cautions
    • Alpha-Adrenergic Agonists
  • Major neurocognitive disorders
    • Drugs used in the treatment of cognitive impairment
    • Future treatments
Prescription Drug Abuse
  • Mental disorders & risk of comorbid prescription drug abuse
  • Classes of drugs that are frequently abused
    • Stimulants
    • Sedative-hypnotics
    • Opiates
  • Strategies for the prevention & early identification of prescription drug abuse



Biography is not currently avaiable.


Alan Bloom, Ph.D., is a professor of pharmacology and toxicology at the Medical College of Wisconsin. He earned a joint Ph.D. in psychology and pharmacology and consults regularly with psychiatrists and attorneys in drug abuse and other pharmacology related cases. Dr. Bloom has conducted extensive research on the impact of drugs of abuse (marijuana, cocaine, etc.) on the brain through use of functional magnetic resonance imaging (fMRI). His studies have been funded by the NIH and other national organizations and reported in an extensive number of publications and presentations. Dr. Bloom has served on the NIDA center grant review panel and is an appointed member of the Controlled Substance Board of the State of Wisconsin. He is a strong and experienced presenter providing lively, information-packed seminars.

Speaker Disclosures:

Speaker Disclosures: Speaker Disclosure: Financial: Alan Bloom is a Professor of Pharmacology and Toxicology at the Medical College of Wisconsin. He receives a speaking honorarium from PESI, Inc.

Non-financial: Alan Bloom is the vice-chair for the State of Wisconsin Controlled Substances Board.
Continuing Education Credits Awarded for Completion of Entire Package
[+] [-] Combined Continuing Education Credit From All Components
Breakdown of Continuing Education Credits by Components
[+] [-] 045900 - Using the DSM-5® and ICD-10: The Changing Diagnosis of Mental Disorders
[+] [-] 045905 - Psychopharmacology for Mental Health Professionals
Psychologists, Counselors, Social Workers, Case Managers, Addiction Counselors, Marriage & Family Therapists, Nurses and other Mental Health Professionals,
  • Counselors
  • ,
  • Psychotherapists
  • ,
  • Psychologists
  • ,
  • Social Workers
  • ,
  • Nurse Practitioners
  • ,
  • Case Managers
  • ,
  • Marriage & Family Therapists
  • ,
  • Addiction Counselors
  • ,
  • Nurses
  • ,
  • Clinical Nurse Specialists
  • ,
  • Pharmacists
  • ,
  • School Psychologists
  • ,
  • Occupational Therapists
  • ,
  • Occupational Therapy Assistants
  • ,
  • Other Mental Health Professionals
  • ,